Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jan;184(1):3-4.
doi: 10.1111/bjd.19544. Epub 2020 Oct 8.

Complete skin clearance and beyond

Affiliations
Comment

Complete skin clearance and beyond

M Schmitt-Egenolf. Br J Dermatol. 2021 Jan.

Abstract

Linked Article: Warren et al. Br J Dermatol 2021; 184:50–59.

PubMed Disclaimer

Comment on

References

    1. Warren RB, Blauvelt A, Poulin Y et al Efficacy and safety of risankizumab vs. secukinumab in patients with moderate to severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy‐assessor‐blinded clinical trial. Br J Dermatol 2021; 184:50–9. - PMC - PubMed
    1. Schmitt‐Egenolf M. Psoriasis therapy in real life: the need for registries. Dermatology 2006; 213:327–30. - PubMed
    1. Blauvelt A, Leonardi CL, Gooderham M et al Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol 2020; 156:649–58. - PMC - PubMed
    1. Gordon KB, Strober B, Lebwohl M et al Efficacy and safety of risankizumab in moderate‐to‐severe plaque psoriasis (UltIMMa‐1 and UltIMMa‐2): results from two double‐blind, randomised, placebo‐controlled and ustekinumab‐controlled phase 3 trials. Lancet 2018; 392:650–61. - PubMed
    1. Geale K, Henriksson M, Jokinen J et al Association of skin psoriasis and somatic comorbidity with the development of psychiatric illness in a nationwide Swedish study. JAMA Dermatol 2020; 156:795–804. - PMC - PubMed